alprazolam

Small moleculeapproved

Approved

Oct 16, 1981

Alprazolam, a benzodiazepine, is used to treat panic disorder and anxiety disorder. Unlike chlordiazepoxide, clorazepate, and prazepam, alprazolam has a shorter half-life and metabolites with minimal activity. Alprazolam may have significant drug interactions involving the hepatic cytochrome P-450 3A4 isoenzyme. Clinically, all benzodiazepines cause a dose-related central nervous system depressant activity varying from mild impairment of task performance to hypnosis. Unlike other benzodiazepines, alprazolam may also have some antidepressant activity, although clinical evidence of this is lacking. CNS agents of the 1,4 benzodiazepine class presumably exert their effects by binding at stereo specific receptors at several sites within the central nervous system. Their exact mechanism of action is unknown. Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. — NCATS

Clinical trial activity

104 trials · 92 clinical orgs · 31 marketing orgs

Phase 1
55
Phase 2
16
Phase 3
8
Phase 4
25

Earliest trial started Nov 1, 1991 (NCT00913341)

Timeline

1980s

  1. Oct 16, 1981

    Upjohn — Earliest FDA Approval

  2. Oct 16, 1981

    Pharmacia & Upjohn — NDA Secondary Org

  3. Oct 16, 1981

    Upjohn — Marketing Organization

  4. Oct 16, 1981

    Upjohn — NDA Organization

1990s

  1. Jan 1, 1991

    Sandoz — Earliest Phase 1 Sponsor(trial)

  2. May 27, 1993

    Roxane Laboratories — Marketing Organization

  3. May 27, 1993

    Boehringer Ingelheim — Marketing Organization

  4. Oct 19, 1993

    DAVA Pharmaceuticals — Marketing Organization

  5. Oct 19, 1993

    Novitium Pharma — Marketing Organization

  6. Oct 31, 1993

    Actavis — Marketing Organization

  7. Oct 31, 1993

    West-Ward Pharmaceutical — Marketing Organization

  8. Oct 31, 1993

    Hikma — Marketing Organization

  9. Jan 27, 1994

    Mylan — Marketing Organization

  10. Feb 16, 1994

    Ani Pharmaceuticals — Marketing Organization

  11. Jul 29, 1994

    Teva — Marketing Organization

  12. Aug 31, 1995

    Watson Pharmaceuticals — Marketing Organization

  13. Dec 29, 1995

    Sandoz — Marketing Organization

  14. Jan 1, 1997

    Earliest Phase 2 Sponsor(trial)

  15. Mar 25, 1998

    Novartis — Marketing Organization

2000s

  1. Jan 17, 2003

    Pharmacia — NDA Secondary Org

  2. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

  3. Jan 19, 2005

    UCB — NDA Secondary Org

  4. Jan 19, 2007

    Apotex — Marketing Organization

  5. May 24, 2007

    Impax Laboratories — Marketing Organization

  6. Oct 15, 2007

    Vintage — Marketing Organization

  7. Oct 15, 2007

    Apax Partners — Marketing Organization

  8. May 30, 2008

    Amneal Pharmaceuticals — Marketing Organization

  9. Sep 25, 2008

    Oxford Pharmaceuticals — Marketing Organization

  10. Oct 17, 2008

    Heritage Pharma — Marketing Organization

  11. Jan 9, 2009

    Par Pharmaceuticals — Marketing Organization

2010s

  1. Jun 17, 2010

    Sun Pharmaceuticals — Marketing Organization

  2. Sep 17, 2010

    Strides Pharma Science — Marketing Organization

  3. Jun 7, 2011

    Aurobindo Pharma — Marketing Organization

  4. Sep 29, 2011

    Anchen Pharmaceuticals, Inc — Marketing Organization

  5. Apr 15, 2015

    Natco Pharma — Marketing Organization

  6. Jul 9, 2018

    Esteve Labs — Marketing Organization

Indications

Studied for

Mechanism of action

Approval history

  • approvedOct 16, 1981

Chemistry & pharmacology

Loading structure…

SMILES

CC1=NN=C2CN=C(C3=CC=CC=C3)C4=CC(Cl)=CC=C4N12
Mol. weight
308.765 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • 8-chloro-1-methyl-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine
  • 8-chloro-1-methyl-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine
  • al-704
  • alprazolam
  • alprazolam
  • alprazolam
  • alprazolam
  • alprazolam
  • alprazolam
  • alprazolam
  • alprazolam
  • alprazolam
  • alprozolam
  • alzolam
  • benzodiacepine
  • benzodiazepine
  • benzodiazepine
  • benzodiazepine
  • jnj-54257099
  • niravam
  • niravam
  • niravam
  • u-31889
  • u-31889
  • xanax
  • xanax
  • xanax
  • xanax
  • xanax
  • xanax
  • xanax
  • xanax
  • xanax xr
  • xanax xr

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07275710N/AFeb 1, 2026Government of Pakistan
NCT07154147Phase 4Aug 12, 2025University of California, San Francisco
NCT07020988Phase 1Jun 12, 2025UCB
NCT06757140Phase 1/Phase 2 (Phase 2)Feb 28, 2025National Institute on Drug Abuse (NIDA), University of Kentucky
NCT05626439Phase 1Dec 7, 2022UCB
NCT05602818Phase 1Nov 15, 2022Takeda
NCT05076617Phase 3Dec 31, 2021UCB
NCT05077904Phase 3Dec 31, 2021UCB
NCT05006079Phase 2Oct 31, 2021Henry Ford Health System, Wayne State University
NCT06097676Phase 4Sep 28, 2021Azurity Pharmaceuticals
NCT04970342Phase 1Jul 16, 2021Acclaro Research Solutions, Inc., Cognitive Research Corporation, NHTSA, University of Iowa
NCT04857307Phase 1Apr 28, 2021UCB
NCT04802746Phase 1Mar 9, 2021UCB
NCT04782388Phase 1Mar 4, 2021UCB
NCT04715269Phase 1/Phase 2 (Phase 2)Dec 25, 2020Sheikh Zayed Medical College, University of Veterinary and Animal Sciences, Lahore
NCT04658732Phase 1Dec 1, 2020Cairo University
NCT04592536Phase 1Oct 6, 2020Cerevel Therapeutics, LLC, Leiden University
NCT04184141Phase 4Dec 1, 2019Istanbul Medeniyet University
NCT03928236N/ASep 30, 2019McMaster University, University of Manitoba
NCT03948243Phase 1Apr 1, 2019Oregon State University, University of Illinois at Chicago
Showing 20 of 104 trials
Page 1 / 6

Organizations

Research & Development (92)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit181732003
UCBFor profit7722021
PRACSFor profit6012005
GlaxoSmithKlineFor profit5512006
National Institute on Drug Abuse (NIDA)Government5231997
ActavisFor profit4412005
Alexza Pharmaceuticals, Inc.For profit4422005
Isfahan UniversityAcademic/Hospital3322011
Kendle International Inc.For profit3012004
MylanFor profit3312004
Cognitive Research CorporationFor profit2012017
Engage Therapeutics Inc.For profit2222018
Hoosier Cancer Research NetworkAcademic/Hospital2222004
Janssen Pharmaceutica NVFor profit2022010
Mclean HospitalAcademic/Hospital2222011
McMaster UniversityAcademic/Hospital2222017
National Institute of Mental Health (NIMH)Government2022006
Orion CorporationFor profit2212009
PharmaKinetics Laboratories Inc.For profit2011991
SandozFor profit2211991
92 organizations
Page 1 / 5

Marketing (42)

OrganizationOrg typeRelationshipDate
ActavisFor profitMKTGOct 31, 1993
ActavisFor profitSYNMay 13, 2010
Amneal PharmaceuticalsFor profitMKTGMay 30, 2008
Anchen Pharmaceuticals, IncFor profitMKTGSep 29, 2011
Ani PharmaceuticalsFor profitMKTGFeb 16, 1994
Ani PharmaceuticalsFor profitSYNFeb 16, 1994
Apax PartnersFor profitMKTGOct 15, 2007
ApotexFor profitMKTGJan 19, 2007
Aurobindo PharmaFor profitMKTGJun 7, 2011
Aurobindo PharmaFor profitSYNJun 7, 2011
Boehringer IngelheimFor profitMKTGMay 27, 1993
DAVA PharmaceuticalsFor profitMKTGOct 19, 1993
Esteve LabsFor profitMKTGJul 9, 2018
Esteve LabsFor profitSYNJul 9, 2018
Heritage PharmaFor profitMKTGOct 17, 2008
HikmaFor profitMKTGOct 31, 1993
HikmaFor profitSYNOct 31, 1993
Impax LaboratoriesFor profitMKTGMay 24, 2007
Impax LaboratoriesFor profitSYNJan 31, 2007
MylanFor profitMKTGJan 27, 1994
MylanFor profitSYNOct 19, 1993
Natco PharmaFor profitSYNApr 15, 2015
Natco PharmaFor profitMKTGApr 15, 2015
NovartisFor profitMKTGMar 25, 1998
Novitium PharmaFor profitMKTGOct 19, 1993
Oxford PharmaceuticalsFor profitMKTGSep 25, 2008
Par PharmaceuticalsFor profitMKTGJan 9, 2009
PharmaciaFor profitNDA2Jan 17, 2003
Pharmacia & UpjohnFor profitNDA2Oct 16, 1981
Roxane LaboratoriesFor profitMKTGMay 27, 1993
SandozFor profitMKTGDec 29, 1995
SandozFor profitSYNJun 30, 2006
Strides Pharma ScienceFor profitMKTGSep 17, 2010
Sun PharmaceuticalsFor profitMKTGJun 17, 2010
Sun PharmaceuticalsFor profitSYNJun 17, 2010
TevaFor profitMKTGJul 29, 1994
UCBFor profitNDA2Jan 19, 2005
UpjohnFor profitMKTGOct 16, 1981
UpjohnFor profitNDAOct 16, 1981
VintageFor profitMKTGOct 15, 2007
Watson PharmaceuticalsFor profitMKTGAug 31, 1995
West-Ward PharmaceuticalFor profitMKTGOct 31, 1993